Jonathan E. Dowell, MD
UT Southwestern Simmons Comprehensive Cancer Center

Jeffrey Gagan, MD, PhD 
UT Southwestern Simmons Comprehensive Cancer Center

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

Congress Co-Chairs

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Kimberly H. Allison, MD
Devicor Medical Products, Inc.: Consulting Fee 

Jennifer J.D. Morrissette, PhD
Bayer HealthCare: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee

Presenting Faculty 

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Jeffrey Gagan, MD, PhD

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Jonathan E. Dowell, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee
Genentech, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee

NCCN Staff Disclosures 

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.